News
Meanwhile, the MHRA has also warned all people seeking treatment with the so-called "skinny jabs" to beware of counterfeit ...
Europe follows a similar pattern, with data from the EU Clinical Trials Information System (CTIS) estimating that less than 0 ...
Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly ...
It is the first fundraising effort at Neuralink since its $280 million Series D round in 2023 and brings the company's total ...
At ASCO 2025, pharmaphorum web editor Nicole Raleigh sat down to discuss key highlights from the Congress with EVERSANA experts.
Only approximately two out of 10 people in the US and three out of 10 people in Europe with certain rare, advanced blood ...
With Axtria Ignite 2025 just around the corner, attention turns to how the life sciences industry is preparing for the next ...
The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...
Ascletis said it has data indicating denifanstat is 98% more effective at treating acne than sarecycline, and 178% better ...
In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head ...
Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...
While all groups have demonstrated an inspiring level of dedication and passion, I have always been moved by patients’ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results